PharmaAQ Expert Forum – Analytical Method – Qualification, Validation & Transfer
Overview
PharmaAQ (Pharma Analysis and Quality) Expert Forum is a technical discussion group comprising of Senior Team Leaders and/or R & D Heads. The forum envisages bringing together both the Pharma and CRO companies at a single platform to discuss the hottest issues and topics for achieving research and business objectives.
The US Food and Drug Administration (US FDA) guidance on process validation describes three stages viz. process design, process performance qualification, and process performance verification. For an analytical method, a method procedure must be monitored efficiently. Before an analytical method can be validated, it is required to define the method development goals and its acceptance criteria usually referred to as analytical target profile. The analytical method development for quality control follows GMP and QbD principles and must be validated for its specificity, accuracy, precision, linearity, range LOD and LOQ etc. Analytical methods are developed using strict validation protocols. The USP states that the transfer of an analytical method is the documented process that qualifies a laboratory (receiving laboratory) to use an analytical method that originated in another laboratory (transferring laboratory), whether that is internal or external to the receiving laboratory.
This discussion forum will be held on November 18, 2021, virtually and is brought to you by the organizing team of Pharma Analysis and Quality conferences in Mumbai on 11-12 October 2018 and Round-table meetings on Nitrosamine Impurities in December 2019 and February 2020. This forum will deliberate upon the various practical aspects of the analytical method pre-validation or qualification, validation, verification and transfer, challenges in developing a robust method, regulatory compliance for analytical methods as well as other issues related to analytical method development and validation.
The H2L Concept- The H2L or Honing to Lead is a novel concept and means honing or refining skills of the team leaders who have the responsibility to steer their team towards achieving the organizational goals. The H2L concept is about refining specifically the technical skills of the team leaders through higher level experts who have vast first-hand experience in the respective areas so that the leader gets an extremely focused conceptual insight into the problem area. This essentially involves bringing together the leaders who share a common platform with the Experts and where the Experts develop an atmosphere conducive to open discussion rather than a regular speaking-listening session.
Who Should Attend
Heads, Vice Presidents, Directors, Senior Managers, Team Leaders, Senior Scientists from Pharma and CRO Organizations working in various domains: Analytical Method Development, Quality control, Formulation Development, Regulatory Affairs, Quality Assurance, Data management/data integrity, and Pharma R&D.
Contacts
Technical Query: Ms. Pooja Sharma, M: 7696325050, Email: p.sharma@glostem.com
Participation Query: Ms. Swati Kanwar, M: 8289015050, Email: s.kanwar@glostem.com
Registration Support: Ms. Ankita Kanwar, M: 7696425050, Email: ankita@glostem.com
Conference Date
18-11-2021
Stephan O. Krause's Biography
Stephan O. Krause
Head of Product Quality Group
AstraZeneca Biologics
Dr Stephan Krause, PhD, is currently Quality Director and PQL Team Leader in Development Quality, AstraZeneca Biologics. He is a results-driven leader with 20 years of technical, managerial, and executive experiences for quality and technical functions within global operations. He is a frequent conference presenter and author and has won multiple industry awards for his publications and leadership in improving industry best practices. Stephan was invited by FDA several times to present an industry perspective to the agency on relevant current topics. He is a member of PDA’s Board of Directors and is co-chair of AMTP Advisory Board and a member of the Advisory Board for Biopharmaceuticals and Regulatory Affairs/Quality.
Gautam Samanta's Biography
Gautam Samanta
Vice President - Quality by Design and Process Scale-up
Cipla Ltd
Dr. Gautam Samanta is Sr. Director and Head of Quality by Design and process scale-up department at Cipla Ltd. Previously, he worked at Dr. Reddy’s Laboratories in API development and implemented QbD and PAT in product development. His areas of focus are in-house development of automated systems, Design of Experiments (DOE) and Quality by Design (QBD) including PAT in Pharmaceutical sciences. He was awarded Ph.D. degree from Jadavpur University, Calcutta. Following his Ph.D. degree, he pursued research as a postdoctoral research fellow at the National Institute of Health Sciences, Japan and then the Texas Tech University, USA. After his postdoctoral research, he joined as a research Assistant Professor at the University of Houston, Texas, USA. He has published more than 50 papers in peer-reviewed international journals including the very prestigious Nature. His work has been cited by more than 1500 researchers. He has also authored 5 book chapters. He is an inventor of three process patents. He is a reviewer of many scientific journals such as Analytical Chemistry, Environmental Science and Technology etc. and also a member of many scientific organizations/committees.
Trupti Tol's Biography
Trupti Tol
Associate Director
Cipla Ltd
Ms Trupti, an Associate Director, leads a dynamic analytical QbD team at Cipla Pharmaceuticals. She has a rich 15 years’ experience in various analytical techniques such as liquid chromatography, Gas chromatography and Particle size analysis. Ms Trupti was instrumental in implementing QbD across the analytical domain at Cipla. She has published her innovative works in different journals including “Journal of Chromatography A”. Ms Trupti has presented her work as a speaker in many National and International conferences held in India and abroad. She has a master’s degree in Organic Chemistry for the University of Mumbai and is also certified Six Sigma Black Belt.
Chait Wannere's Biography
Chait Wannere
Senior Director, Analytical Development
TCG GreenChem
Dr Chait Wannere, Senior Director, Analytical Development, TCG GreenChem, USA. He is High energy scientific and managerial leader with 15 years of experience in the pharmaceutical industry with broad knowledge and direct involvement in drug development processes. Extensive knowledge of cGMP activities. Involved with CMC filings of several products in US and ROW.
- Instrumental in delivering billion-dollar drugs in an accelerated manner to the market while working at Forest Research Institute and Merck Research Laboratories (MSD in Europe).
- Thorough knowledge and first-hand experience of global regulatory requirements (US, Europe and ROW), analytical development, validations, QC, Extractables/Leachables, and pre-formulation activities (polymorphism and salt-screening).
- Skilled at characterization of drug products, RSMs, reactive intermediates, and drug substances (small molecules and peptides). Experienced in development of analytical techniques for analyzing SODs, ODTs, semisolids, suspensions, and sterile injectables and vaccines.
- Results driven, strategic, and structured professional with proficiency in planning and leading early and late phase projects.
- 2019:Supported analytical, formulation, and CMC in approval of Flunixin Injectable reformulation for Europe.
- 2018: Received the Innovation award at Merck for the expansion of lifecycle management of the Fluralaner franchise to include Bravecto 1 Month.
- 2008-2015: Supported 7 Forest products (including, Linzess, Vraylar, Savella, and Fetzima) at various development stages, including lifecycle stages, and was analytical lead on 4 Merck products (Bravecto 1 Month, Flunixin Injectable, Fluralaner for Cattle, and MOF).
- About 40 publications: including internationally top scientific journals, reviews and book chapter, H-index of 25 and RG Score of 33.4
- Served as Reviewer for Journal of Physical Chemistry, Chemical Reviews, and Journal of Organic Chemistry
- Member of IQ team for Lean Stability and Risk Based Stability approach.
Bhaskar Kolte's Biography
Bhaskar Kolte
Associate Director -ARD
Perrigo Laboratories India Pvt Ltd
Conference Agenda
- Analytical Method Development-Critical Review
- Analytical Method Qualification and Validation
- Method Validation Protocols
- Analytical Method Transfer-Best Practices
Agenda Topics for Analytical Method – Qualification, Validation & Transfer
-
Analytical Method Development-Critical Review
- Analytical target profile, Regulatory guidance, and challenges
-
Analytical Method Qualification and Validation
- Instrument and reagent qualification, Method robustness and verification
-
Method Validation Protocols
- Protocol characteristics, Acceptance criteria, Handling deviations
-
Analytical Method Transfer-Best Practices
- Transfer method critical concerns, site evaluation, transfer reports
Speakers & Panelists
Professor & Head,
NIPER Mohali,
Stephan O. Krause's Biography
Stephan O. Krause
Head of Product Quality Group
AstraZeneca Biologics
Dr Stephan Krause, PhD, is currently Quality Director and PQL Team Leader in Development Quality, AstraZeneca Biologics. He is a results-driven leader with 20 years of technical, managerial, and executive experiences for quality and technical functions within global operations. He is a frequent conference presenter and author and has won multiple industry awards for his publications and leadership in improving industry best practices. Stephan was invited by FDA several times to present an industry perspective to the agency on relevant current topics. He is a member of PDA’s Board of Directors and is co-chair of AMTP Advisory Board and a member of the Advisory Board for Biopharmaceuticals and Regulatory Affairs/Quality.
Head of Product Quality Group,
AstraZeneca Biologics,
USA
Gautam Samanta's Biography
Gautam Samanta
Vice President - Quality by Design and Process Scale-up
Cipla Ltd
Dr. Gautam Samanta is Sr. Director and Head of Quality by Design and process scale-up department at Cipla Ltd. Previously, he worked at Dr. Reddy’s Laboratories in API development and implemented QbD and PAT in product development. His areas of focus are in-house development of automated systems, Design of Experiments (DOE) and Quality by Design (QBD) including PAT in Pharmaceutical sciences. He was awarded Ph.D. degree from Jadavpur University, Calcutta. Following his Ph.D. degree, he pursued research as a postdoctoral research fellow at the National Institute of Health Sciences, Japan and then the Texas Tech University, USA. After his postdoctoral research, he joined as a research Assistant Professor at the University of Houston, Texas, USA. He has published more than 50 papers in peer-reviewed international journals including the very prestigious Nature. His work has been cited by more than 1500 researchers. He has also authored 5 book chapters. He is an inventor of three process patents. He is a reviewer of many scientific journals such as Analytical Chemistry, Environmental Science and Technology etc. and also a member of many scientific organizations/committees.
Vice President - Quality by Design and Process Scale-up,
Cipla Ltd,
Trupti Tol's Biography
Trupti Tol
Associate Director
Cipla Ltd
Ms Trupti, an Associate Director, leads a dynamic analytical QbD team at Cipla Pharmaceuticals. She has a rich 15 years’ experience in various analytical techniques such as liquid chromatography, Gas chromatography and Particle size analysis. Ms Trupti was instrumental in implementing QbD across the analytical domain at Cipla. She has published her innovative works in different journals including “Journal of Chromatography A”. Ms Trupti has presented her work as a speaker in many National and International conferences held in India and abroad. She has a master’s degree in Organic Chemistry for the University of Mumbai and is also certified Six Sigma Black Belt.
Associate Director,
Cipla Ltd,
Chait Wannere's Biography
Chait Wannere
Senior Director, Analytical Development
TCG GreenChem
Dr Chait Wannere, Senior Director, Analytical Development, TCG GreenChem, USA. He is High energy scientific and managerial leader with 15 years of experience in the pharmaceutical industry with broad knowledge and direct involvement in drug development processes. Extensive knowledge of cGMP activities. Involved with CMC filings of several products in US and ROW.
- Instrumental in delivering billion-dollar drugs in an accelerated manner to the market while working at Forest Research Institute and Merck Research Laboratories (MSD in Europe).
- Thorough knowledge and first-hand experience of global regulatory requirements (US, Europe and ROW), analytical development, validations, QC, Extractables/Leachables, and pre-formulation activities (polymorphism and salt-screening).
- Skilled at characterization of drug products, RSMs, reactive intermediates, and drug substances (small molecules and peptides). Experienced in development of analytical techniques for analyzing SODs, ODTs, semisolids, suspensions, and sterile injectables and vaccines.
- Results driven, strategic, and structured professional with proficiency in planning and leading early and late phase projects.
- 2019:Supported analytical, formulation, and CMC in approval of Flunixin Injectable reformulation for Europe.
- 2018: Received the Innovation award at Merck for the expansion of lifecycle management of the Fluralaner franchise to include Bravecto 1 Month.
- 2008-2015: Supported 7 Forest products (including, Linzess, Vraylar, Savella, and Fetzima) at various development stages, including lifecycle stages, and was analytical lead on 4 Merck products (Bravecto 1 Month, Flunixin Injectable, Fluralaner for Cattle, and MOF).
- About 40 publications: including internationally top scientific journals, reviews and book chapter, H-index of 25 and RG Score of 33.4
- Served as Reviewer for Journal of Physical Chemistry, Chemical Reviews, and Journal of Organic Chemistry
- Member of IQ team for Lean Stability and Risk Based Stability approach.
Senior Director, Analytical Development,
TCG GreenChem,
USA
Bhaskar Kolte's Biography
Bhaskar Kolte
Associate Director -ARD
Perrigo Laboratories India Pvt Ltd
Associate Director -ARD,
Perrigo Laboratories India Pvt Ltd,
Analytical Method – Qualification, Validation & Transfer
Download Programme PDFThursday, 18th November 2021
| 13:30 |
Test Run and Web Checks
|
| 14:30 |
Welcome Address and Introduction to the Experts Sanjay Bajaj, CEO & MD, Glostem Private Limited, India |
| 14:50 |
Select Emerging Requirements w.r.t Method Validation Saranjit Singh, Professor & Head, NIPER Mohali, |
| 15:10 |
Open Discussion/ QA Session |
| 15:15 |
Significance of Implementing QbD in Analytical Method Development – A Case StudyOverview Trupti Tol, Associate Director, Cipla Ltd, |
| 15:30 |
Open Discussion/ QA Session |
| 15:40 |
Analytical Procedure Lifecycle Bhaskar Kolte, Associate Director -ARD, Perrigo Laboratories India Pvt Ltd, |
| 15:55 |
Open Discussion/ QA Session |
| 16:05 |
Reference Standard Qualification Chait Wannere, Senior Director, Analytical Development, TCG GreenChem, USA |
| 16:20 |
Open Discussion/ QA Session |
| 16:35 |
AMQ, AMV, APT Studies for Analytical Platform Technology (APT) Methods Stephan O. Krause, Head of Product Quality Group, AstraZeneca Biologics, USA |
| 17:00 |
Open Discussion/ QA Session |
| 17:15 |
Rap Session |
| 17:30 |
Closing Remarks (Prof Saranjit Singh) |
| 17:35 |
Vote of Thanks (Dr Sanjay Bajaj) |